MedPath

Evaluation of the Stinging Potential in Human Eyes

Not Applicable
Completed
Conditions
Sunscreen Agents
Interventions
Drug: BAY 987516 (Y65-122)
Drug: BAY 987516 (Y65-118)
Drug: Control
Registration Number
NCT02872207
Lead Sponsor
Bayer
Brief Summary

The objective of this study was to compare the human eye stinging potential of experimental formulas and an industry standard shampoo mixture. The study was conducted under the supervision of a Board Certified Ophthalmologist.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Male or female subjects, aged 18 to 60 years
  • No medical conditions of the eyes as determined by the subjects' medical history and confirmed by ophthalmologist
  • Subjects do not wear contact lenses or, if he/she does wear contact lenses, is willing to refrain from wearing these during the day of and day after the study
  • Subject is willing to have the test materials instilled into the eyes and follow all protocol requirements
  • Subject is willing to refrain from using false eyelashes of any type or any topical prescription, OTC or cosmetic products on their eyes, eyelids, eyelashes or the peri-orbital areas of the face on the day of the study.
  • Subjects should refrain from use of make-up on testing day
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Suncare agent 1 + controlBAY 987516 (Y65-122)Application of control and test product into one of the subjects two eyes.
Suncare agent 1 + controlControlApplication of control and test product into one of the subjects two eyes.
Suncare agent 2 + controlBAY 987516 (Y65-118)Application of control and test product into one of the subjects two eyes.
Suncare agent 2 + controlControlApplication of control and test product into one of the subjects two eyes.
Primary Outcome Measures
NameTimeMethod
Post installation discomfort upon awakening was assessed using a 5-category intensity scoreat 24 hours
Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject, and a 5-category intensity scale.up to 24 hours
Tearing/Lacrimation was assessed by the Ophthalmologist using a 5-category assessment score for each of the categoriesup to 24 hours
Objective inflammation was assessed by the Ophthalmologist using a 5-category assessment score for each of the categoriesat 24 hours
Post installation pain/stinging was assessed using a 5-category intensity scoreat 24 hours
Post installation itching was assessed using a 5-category intensity scoreat 24 hours
Post installation dryness was assessed using a 5-category intensity scoreat 24 hours
Post installation scratchiness was assessed using a 5-category intensity scoreat 24 hours
Post installation discomfort preventing sleep was assessed using a 5-category intensity scoreat 24 hours
Post installation excessive discharge upon awakening was assessed using a 5-category intensity scoreat 24 hours
Post installation pain in bright sunlight was assessed using a 5-category intensity scoreat 24 hours
Secondary Outcome Measures
NameTimeMethod
Number of adverse events as a measure of safety and tolerabilitayat 24 hours
© Copyright 2025. All Rights Reserved by MedPath